Protein Engineering for Therapeutics, Part A
- 1st Edition, Volume 502 - January 11, 2012
- Imprint: Academic Press
- Editors: K. Dane Wittrup, Gregory L. Verdine
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 4 1 6 0 3 9 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 3 9 1 4 7 4 - 3
This volume of Methods in Enzymology looks at Protein Engineering for Therapeutics. The chapters provide an invaluable resource for academics, researchers and students alike. Wi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis volume of Methods in Enzymology looks at Protein Engineering for Therapeutics. The chapters provide an invaluable resource for academics, researchers and students alike. With an international board of authors, this volume is split into sections that cover subjects such as Antibodies, Protein conjugates, Peptides, Enzymes and Scaffolds
- Chapters provide an invaluable resource for academics, researchers and students alike
- Iinternational board of authors
- This volume is split into sections that cover subjects such as Antibodies, Protein conjugates, Peptides, Enzymes and Scaffolds
Biochemists, biophysicists, molecular biologists, analytical chemists, and physiologists
Series Page
Contributors
Preface
Volume in Series
Simplified Synthetic Antibody Libraries
1. Introduction
2. Materials
3. Methods
Generation of Dual-Variable-Domain Immunoglobulin Molecules for Dual-Specific Targeting
1. Introduction
2. Design of DVD-Ig™ Molecules
3. Cloning and Expression of DVD-Ig™ Molecules
4. Molecular Characterization of DVD-Ig™ Proteins
5. Functional Characterization of DVD-Ig™ Proteins
6. Concluding Remarks
Acknowledgments
Discovery of Internalizing Antibodies to Tumor Antigens from Phage Libraries
1. Introduction
2. Selection of Tumor Cell-Specific Internalizing scFv from Phage Antibody Libraries
3. Profiling the Specificity of Phage Antibodies on Tumor Cells Using Flow Cytometry
4. Identification of the Cognate Antigen Recognized by Tumor-Specific scFv by Using Mass Spectrometry
5. Selection of Antigen-Specific Phage Antibodies by Sequential Selection on Tumor Cells Followed by Selection on Yeast Cells Displaying Specific Tumor Antigens
Optimizing Properties of Antireceptor Antibodies Using Kinetic Computational Models and Experiments
1. Introduction: Valence, Affinity, and Avidity in Antibodies
2. Quantifying Antibody Cross-linking Strength Using “VFC” Models of Antibody Binding to Cell-Surface Receptors
3. Workflow for Quantifying Antibody Cross-linking Strength
4. Model Applications and Insights
Acknowledgments
Cell-Specific siRNA Delivery by Peptides and Antibodies
1. Introduction
2. Cationic Cell Permeable Peptides
3. Solid Biodegradable Polymer and Vesicular (Liposomal) Systems
Acknowledgments
Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues
1. Antibody Reduction
2. Monitoring Antibody Reduction
3. Conjugation with Maleimido Drug-Linker
4. Purification Methods
5. Small-Scale Conjugations for Early ADC Discovery
6. Procedure for Solid-Phase Conjugation
7. Determination of Drug Loading
8. Determination of Unconjugated Drug Content
9. Conclusions
Building and Characterizing Antibody-Targeted Lipidic Nanotherapeutics
1. Introduction
2. Preparation of Immunoliposomes
3. Physicochemical Characterization of Immunoliposomes
4. In Vitro and In Vivo Characterization of Immunoliposomal Therapeutics
Cell-Targeting Fusion Constructs Containing Recombinant Gelonin
1. Introduction
2. Engineered Proteins Targeting Her2/neu
3. rGel/BLyS Targeting Malignant B-Cells
4. VEGF121/rGel Targeting Tumor Vasculature and Skeletal Metastases
Fusions of Elastin-Like Polypeptides to Pharmaceutical Proteins
1. Introduction
2. Protein ELP Fusion Design
3. Recursive Directional Ligation by Plasmid Reconstruction
4. Expression and Purification of Protein ELP Fusions
5. Physical Characterization of Protein ELP Fusions
6. Conclusions
Acknowledgment
Oral Enzyme Therapy for Celiac Sprue
1. Introduction
2. Lead Identification
3. Assay Development
4. Gram-Scale Production and Formulation
5. Lead Optimization for Next-Generation Proteases
6. Summary and Outlook
Rational Design and Evaluation of Mammalian Ribonuclease Cytotoxins
1. Introduction
2. Attributes of Cytotoxic ptRNases
3. Assays to Evaluate the Cytotoxicity of ptRNases
4. Prospectus
Acknowledgments
Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer
1. Introduction: Amino Acid Depletion as a Chemotherapeutic Strategy
2. Method I. Combinatorial Deimmunization
3. Method II. Engineering Therapeutically Relevant Substrate Specificities into a Human Enzyme
4. Method III. Improving the Kinetics and Stability of a Human Enzyme
5. Concluding Remarks
- Edition: 1
- Volume: 502
- Published: January 11, 2012
- No. of pages (Hardback): 392
- No. of pages (eBook): 392
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780124160392
- eBook ISBN: 9780123914743
Read Protein Engineering for Therapeutics, Part A on ScienceDirect